271. 強直性脊椎炎 Ankylosing spondylitis Clinical trials / Disease details


臨床試験数 : 563 薬物数 : 372 - (DrugBank : 72) / 標的遺伝子数 : 41 - 標的パスウェイ数 : 145

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00432653
(ClinicalTrials.gov)
March 20076/2/2007Open Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing SpondylitisOpen Label Clinical Trial With Rituximab (MabThera ®) in Ankylosing SpondylitisAnkylosing SpondylitisDrug: rituximabCharite University, Berlin, GermanyHoffmann-La RocheNot yet recruiting18 Years65 YearsBoth20Phase 2/Phase 3Germany
2EUCTR2006-002306-64-DE
(EUCTR)
28/12/200604/10/2006Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab - Ritux-AS-01Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab - Ritux-AS-01 Moderate to severe ankylosing spondylitis who have had an inadequate response to or do not tolerate conventional therapy including NSAIDs, DMARDs and TNF alpha inhibitorsTrade Name: Rituximab/ Mabthera
Product Name: MabThera
Product Code: Ro45-2294
INN or Proposed INN: rituximab
Charité UniversitaetsmedizinNULLNot RecruitingFemale: yes
Male: yes
Germany
3EUCTR2005-005358-27-GB
(EUCTR)
12/07/200610/04/2006Efficacy of Rituximab (Mabthera) in active ankylosing spondylitis: a clinical and magnetic resonance imaging study - Rituximab in ASEfficacy of Rituximab (Mabthera) in active ankylosing spondylitis: a clinical and magnetic resonance imaging study - Rituximab in AS Ankylosing spondylitis (AS) is an inflammatory condition primarily affecting the spine. The disease may remain symptomatic and progressive life-long. It is part of the family of spondyloarthropathies which also comprises psoriatic arthritis, reactive arthritis and enteropathic arthritis.Trade Name: MabThera 500University Hospital of North StaffordshireNULLNot Recruiting Female: yes
Male: yes
10 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): noUnited Kingdom